Interaksi Bumetanid dan Fosinopril dan hidroklorotiazid

Bumetanid dan Fosinopril dan hidroklorotiazid: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Bumetanid (Bumetanide) · berlaku sejak 2025-12-17

Mayor

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Moderat

Prevention of hypokalemia requires particular attention in the following conditions: patients receiving digitalis and diuretics for congestive heart failure, hepatic cirrhosis and ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, certain diarrheal states, or other states where hypokalemia is thought to represent particular…

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

In these test animals bumetanide was 5 to 6 times more potent than furosemide and, since the diuretic potency of bumetanide is about 40 to 60 times furosemide, it is anticipated that blood levels necessary to produce ototoxicity will rarely be achieved.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Like other members of this class of diuretics, bumetanide probably shares this risk.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Lithium Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Fosinopril dan hidroklorotiazid (Fosinopril Sodium and Hydrochlorothiazide) · berlaku sejak 2024-04-28

Moderat

Symptomatic hypotension is most likely to occur in patients who have been volume- and/or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

In such patients, fosinopril sodium and hydrochlorothiazide therapy should be started under close medical supervision; they should be followed closely for the first 2 weeks of treatment and whenever the dose of fosinopril or diuretic is increased.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

In some studies of hypertensive patients with unilateral or bilateral renal artery stenosis, treatment with ACE inhibitors has been associated with increases in blood urea nitrogen and serum creatinine; these increases were reversible upon discontinuation of ACE inhibitor therapy, concomitant diuretic therapy, or both.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Some ACE-inhibitor-treated hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when the ACE inhibitor has been given concomitantly with a diuretic.

Peringatanberdasarkan golongan obatLihat label di DailyMed
Moderat

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.